This playbook explores how an integrated, international and sustainable partner can de-risk precision drug development and speed time to market.
As precision medicine programs featuring biomarker-driven oncology studies have become central to sponsors’ drug development strategies, they have also introduced added complexity. Life sciences leaders must now consider whether and how best to consolidate their current lab approach. Engaging with an integrated, international and sustainable partner has emerged as a top strategic choice.
This playbook explores three key attributes of an effective testing program, as well as how to find the right partner to get you there. It is a strategy that can de-risk development, improve trial diversity and accelerate time-to-market. Highlights include:
- An integrated solution that consolidates testing needs from early- to late-stage into a single partner.
- Why a global footprint that supports an international trial strategy is crucial in the precision medicine era.
- How a focus on sustainability can achieve cost efficiencies and meet rigorous environmental, social and governance standards.
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and Labcorp
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and Labcorp
